CCM
DNLI icon

Covington Capital Management’s Denali Therapeutics DNLI Stock Holding History

Covington Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$31K – 738
2017
Q4 		$31K Buy
+2,000
New +$35.9K ﹤0.01% 516

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Covington Capital Management's DNLI Position: Q1 2018 in Review

Covington Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 2,000 shares — an estimated $31K sold.

Covington Capital Management first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $31K in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

  • Covington Capital Management reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Covington Capital Management sold 2,000 Denali Therapeutics shares in Q1 2018, an estimated $31K.
  • Covington Capital Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
  • Covington Capital Management's Denali Therapeutics position peaked at $31K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on Covington Capital Management's 13F filing for Q1 2018, filed 11 May 2018.